These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19771884)

  • 1. [Research on foreign countries laws and regulations on surveillance and reporting of postmarketing drugs adverse reactions].
    Tian F; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2009 Jun; 34(11):1464-7. PubMed ID: 19771884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
    Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
    Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety monitoring of new anti-malarials in immediate post-marketing phase.
    Edwards IR
    Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drugs: watch out for unexpected adverse effects.
    Prescrire Int; 2002 Oct; 11(61):150-1. PubMed ID: 12378747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interview -- drug legislation -- reporting unexpected adverse drug reactions].
    Ludwig WD
    Pneumologie; 2009 Sep; 63(9):479-80. PubMed ID: 19764017
    [No Abstract]   [Full Text] [Related]  

  • 6. [French system of drug surveillance].
    Imbs JL; Castot A; Begaud B; Larousse C; Blayac JP; Alexandre JM
    Bull Acad Natl Med; 1998; 182(7):1383-91; discussion 1392-3. PubMed ID: 9916332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug surveillance: concepts, objectives, and methods].
    Susano RC; Laborinho Fialho L; de Quirós JF
    Acta Med Port; 1992 Dec; 5(11):595-602. PubMed ID: 1293954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug surveillance and adverse reactions to drugs. The literature and importance of historical data].
    Mariani L; Minora T; Ventresca GP
    Clin Ter; 1996 Dec; 147(12):653-72. PubMed ID: 9296925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
    Shani S; Yahalom Z
    Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669
    [No Abstract]   [Full Text] [Related]  

  • 10. [Drug handling in a legal perspective].
    Andersen SE; Dalhoff KP
    Ugeskr Laeger; 2002 Sep; 164(40):4651-5. PubMed ID: 12380117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global harmonization is not all that global: divergent approaches in drug safety.
    Castle GH; Kelly B
    Food Drug Law J; 2008; 63(3):601-22. PubMed ID: 19031662
    [No Abstract]   [Full Text] [Related]  

  • 12. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 13. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
    Zhang W; Xie YM; Yu WY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacovigilance as new direction of research].
    Gaszner G; Makkos Z; Gaszner P
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):194-8. PubMed ID: 16496484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thought on several problems of clinical revaluation of post-marketing herb research].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(12):1641-3. PubMed ID: 20815225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety learning from drugs of the same class: room for improvement.
    Stefansdottir G; Knol MJ; Arnardottir AH; van der Elst ME; Grobbee DE; Leufkens HG; De Bruin ML
    Clin Pharmacol Ther; 2012 May; 91(5):872-80. PubMed ID: 22453192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of spontaneous reporting of adverse drug reactions (ARDs) in Zimbabwe.
    Ball D
    Cent Afr J Med; 2000 Jan; 46(1):23-4. PubMed ID: 14674204
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program.
    Lange-Asschenfeldt C; Grohmann R; Lange-Asschenfeldt B; Engel RR; Rüther E; Cordes J
    J Clin Psychiatry; 2009 Sep; 70(9):1258-65. PubMed ID: 19538904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.